Table 7.

Results of longitudinal safety analysis using phase pairs

	Fraction (%) of patients who reported adverse events in the group with dosage of 8 mg/week or lower	Fraction (%) of patients who reported adverse events in the group with dosage over 8 mg/week	Regression coefficientb	P valuec
Primary endpointa	4.88	5.16	−0.0351	0.63
Secondary endpoint 1	0.92	1.10	0.119	0.45
Secondary endpoint 2	3.66	4.02	-0.0096	0.91
Secondary endpoint 3	14.60	16.90	0.0384	0.38

^aSee text for the definitions of the endpoints

^bMaximum-likelihood estimate of the slope in the logistic regression analysis

^cP value of the test for the null hypothesis that the slope is zero